Skip to main content

Chronic Fatigue Syndrome

3
Pipeline Programs
8
Companies
9
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
1
0
0
1
1
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

7 companies ranked by most advanced pipeline stage

Pfizer
PfizerNEW YORK, NY
1 program
1
SildenafilPhase 41 trial
Active Trials
NCT00598585Completed12Est. Dec 2010
AIM ImmunoTech
AIM ImmunoTechFL - Ocala
2 programs
1
AmpligenPhase 31 trial
Poly I: Poly C12UN/A1 trial
Active Trials
NCT00215813Temporarily Not Available
NCT00215800Completed234Est. Feb 2004
PharmaLundensis
PharmaLundensisSweden - Lund
1 program
1
IodoCarbPhase 1/21 trial
Active Trials
NCT01793415Unknown40Est. Dec 2013
Innovation Pharmaceuticals
2 programs
ActiveN/A1 trial
Coenzyme Q10 plus NADHN/A1 trial
Active Trials
NCT04301609Completed67Est. Jan 2023
NCT03186027Completed282Est. Sep 2021
DxTerity
DxTerityCA - Torrance
1 program
Exploring the Biological Basis of Chronic Fatigue SyndromeN/A1 trial
Active Trials
NCT04859257Completed380Est. Dec 2021
Arctic Therapeutics
Arctic TherapeuticsIceland - Reykjavik
1 program
Interdisciplinary complex interventionN/A1 trial
Active Trials
NCT05130099Unknown150Est. Jun 2025
UCB Pharma
UCB PharmaBelgium - Brussels
1 program
Sodium oxybatePHASE_41 trial
Active Trials
NCT01584934Withdrawn0Est. Dec 2015

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
UCB PharmaSodium oxybate
PfizerSildenafil
AIM ImmunoTechAmpligen
PharmaLundensisIodoCarb
Arctic TherapeuticsInterdisciplinary complex intervention
Innovation PharmaceuticalsActive
DxTerityExploring the Biological Basis of Chronic Fatigue Syndrome
Innovation PharmaceuticalsCoenzyme Q10 plus NADH

Clinical Trials (9)

Total enrollment: 1,165 patients across 9 trials

NCT01584934UCB PharmaSodium oxybate

Sodium Oxybate in Patients With Chronic Fatigue Syndrome.

Start: Jun 2013Est. completion: Dec 20150
Phase 4Withdrawn
NCT00598585PfizerSildenafil

Use of Sildenafil (Viagra) to Alter Fatigue, Functional Status and Impaired Cerebral Blood Flow in Patients With CFS

Start: Jul 2002Est. completion: Dec 201012 patients
Phase 4Completed
NCT00215800AIM ImmunoTechAmpligen

The Study of the Safety and Efficacy of Ampligen in Chronic Fatigue Syndrome

Start: Dec 1998Est. completion: Feb 2004234 patients
Phase 3Completed
NCT01793415PharmaLundensisIodoCarb

Treatment of Chronic Fatigue Syndrome (CFS) With Iodinated Activated Charcoal (IodoCarb®)

Start: Feb 2013Est. completion: Dec 201340 patients
Phase 1/2Unknown
NCT00215813AIM ImmunoTechPoly I: Poly C12U

Ampligen in Chronic Fatigue Syndrome

N/ATemporarily Not Available
NCT05130099Arctic TherapeuticsInterdisciplinary complex intervention

A Complex Intervention for Chronically Fatigued Lymphoma Survivors

Start: Nov 2021Est. completion: Jun 2025150 patients
N/AUnknown
NCT04301609Innovation PharmaceuticalsActive

Clinical Trial to Assess the Improvement of Fatigue, Sleep Problems, Anxiety / Depression, Neurovegetatives Alterations and Quality of Life After the Administration of ImmunoVita® in Chronic Fatigue Syndrome Patients

Start: Nov 2021Est. completion: Jan 202367 patients
N/ACompleted
NCT04859257DxTerityExploring the Biological Basis of Chronic Fatigue Syndrome

Exploring the Biological Basis of Chronic Fatigue Syndrome

Start: May 2021Est. completion: Dec 2021380 patients
N/ACompleted
NCT03186027Innovation PharmaceuticalsCoenzyme Q10 plus NADH

Coenzyme Q10 Plus NADH Supplementation in Chronic Fatigue Syndrome/Myalgic Encephalomyelitis

Start: Jun 2017Est. completion: Sep 2021282 patients
N/ACompleted

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

1 late-stage (Phase 3) programs, potential near-term approvals
8 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.